The blood-brain barrier prevents the passage of most therapeutic drugs to the organ. The barrier is very selective of what's allowed to pass through, but that does not hold good in the case of exosomes.
The investigators at Chapel Hill loaded used catalase, a powerful antioxidant into the exosomes, which were gathered from macrophage white blood cells. Delivering an antioxidant at the site of inflammation in the brain may be therapeutic as Parkinson's and many other neurological diseases cause inflammation in the brain.
The study proved that exosome-based catalase formulations have a potential to be a versatile strategy to treat inflammatory and neurodegenerative disorders.